Metilación de CDH1 en lavados peritoneales como factor pronóstico de cáncer gástrico

Autores/as

DOI:

https://doi.org/10.33448/rsd-v11i2.25758

Palabras clave:

Cáncer gástrico; Metástasis peritoneal; Metilación; CDH1; Progresión tumoral.

Resumen

El cáncer gástrico es un importante problema de salud pública, considerado el quinto cáncer más diagnosticado en el mundo. La metástasis peritoneal es una de las principales causas de mortalidad relacionada con el cáncer gástrico. La hipermetilación de los genes supresores de tumores es un factor prometedor para el desarrollo de biomarcadores predictivos. En los tumores gástricos, la expresión reducida del gen supresor CDH1 contribuye a la invasión tumoral y al desencadenamiento de metástasis. Nuestro objetivo fue evaluar el perfil de metilación de la región promotora del gen CDH1 como indicador de metástasis peritoneal en pacientes con cáncer gástrico. El perfil de metilación de CDH1 se evaluó en 47 muestras de lavado peritoneal de pacientes con cáncer gástrico mediante PCR de secuenciación con bisulfito (BSP). Treinta y tres sitios CpG en la región promotora de CDH1 se evaluaron individualmente. Las muestras con ≥ 10 % de sitios CpG metilados se consideraron hipermetiladas. El análisis estadístico se realizó mediante la prueba exacta de Fisher, utilizando el programa R-Studio (p≤0.05). Veintinueve (62%) muestras mostraron hipermetilación en la región promotora de CDH1, con metilación preferencial en los sitios CpG ubicados en la región 5' aguas arriba del gen. El análisis estadístico mostró que la hipermetilación de CDH1 fue significativamente diferente en pacientes con estadios avanzados de profundidad de invasión tumoral (p = 0,03). Nuestros resultados sugieren que el análisis de la metilación del gen CDH1 es una herramienta útil para predecir la progresión tumoral y la invasividad en pacientes con cáncer gástrico y podría tener un gran impacto en el campo de la medicina oncológica de precisión.

Citas

Bentrem, D., Wilton, A., Mazumdar, M., Brennan, M., & Coit, D. (2005). The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Annals of Surgical Oncology, 12(5), 347–353. https://doi.org/10.1245/aso.2005.03.065

Bergman, Y., & Cedar, H. (2013). DNA methylation dynamics in health and disease. Nature Structural & Molecular Biology, 20(3), 274–281. https://doi.org/10.1038/nsmb.2518

Borges, B. do N., Santos, E. da S., Bastos, C. E. M. C., Pinto, L. C., Anselmo, N. P., Quaresma, J. A. S., Calcagno, D. Q., Burbano, R. M. R., & Harada, M. L. (2010). Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. Anticancer Research, 30(6), 2225–2233.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492

Bruner, H. C., & Derksen, P. W. B. (2018). Loss of E-cadherin-dependent cell–cell adhesion and the development and progression of cancer. Cold Spring Harbor Perspectives in Biology, 10(3), a029330. https://doi.org/10.1101/cshperspect.a029330

Caldeira, J. R. F., Prando, E. C., Quevedo, F. C., Neto, F. A. M., Rainho, C. A., & Rogatto, S. R. (2006). CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer, 6(1), 48. https://doi.org/10.1186/1471-2407-6-48

Corn, P. G., Heath, E. I., Heitmiller, R., Fogt, F., Forastiere, A. A., Herman, J. G., & Wu, T. T. (2001). Frequent hypermethylation of the 5’ CpG island of E-cadherin in esophageal adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7(9), 2765–2769.

Corn, P. G., Smith, B. D., Ruckdeschel, E. S., Douglas, D., Baylin, S. B., & Herman, J. G. (2000). E-cadherin expression is silenced by 5’ CpG island methylation in acute leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 6(11), 4243–4248.

Dumitrescu, R. G. (2018). Early epigenetic markers for precision medicine. Methods in Molecular Biology (Clifton, N.J.), 1856, 3–17. https://doi.org/10.1007/978-1-4939-8751-1_1

Fu, D.-G. (2015). Epigenetic alterations in gastric cancer (Review). Molecular Medicine Reports, 12(3), 3223–3230. https://doi.org/10.3892/mmr.2015.3816

Fujiwara, Y., Doki, Y., Taniguchi, H., Sohma, I., Takiguchi, S., Miyata, H., Yamasaki, M., & Monden, M. (2007). Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 10(4), 197–204. https://doi.org/10.1007/s10120-007-0436-5

Gao, P., Wang, S., Jing, F., Zhan, J., & Wang, Y. (2017). microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1/2/Slug/ E-cadherin signaling. Cancer Biomarkers: Section A of Disease Markers, 19(1), 11–20. https://doi.org/10.3233/CBM-160167

Hiraki, M., Kitajima, Y., Koga, Y., Tanaka, T., Nakamura, J., Hashiguchi, K., Noshiro, H., & Miyazaki, K. (2011). Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Annals of Surgical Oncology, 18(10), 3013–3019. https://doi.org/10.1245/s10434-011-1636-0

Hiraki, M., Kitajima, Y., Sato, S., Nakamura, J., Hashiguchi, K., Noshiro, H., & Miyazaki, K. (2010). Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World Journal of Gastroenterology: WJG, 16(3), 330–338. https://doi.org/10.3748/wjg.v16.i3.330

Holubeková, V., Mendelová, A., Grendár, M., Meršaková, S., Kapustová, I., Jašek, K., Vaňochová, A., Danko, J., & Lasabová, Z. (2016). Methylation pattern of CDH1 promoter and its association with CDH1 gene expression in cytological cervical specimens. Oncology Letters, 12(4), 2613–2621. https://doi.org/10.3892/ol.2016.5004

Hoskovec, D., Varga, J., Dytrych, P., Konecna, E., & Matek, J. (2017). Peritoneal lavage examination as a prognostic tool in cases of gastric cancer. Archives of Medical Science: AMS, 13(3), 612–616. https://doi.org/10.5114/aoms.2016.64044

Japanese Gastric Cancer Association. (2017). Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 20(1), 1–19. https://doi.org/10.1007/s10120-016-0622-4

Jones, P. A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature Reviews. Genetics, 13(7), 484–492. https://doi.org/10.1038/nrg3230

Katoh, M. (2005). Epithelial-mesenchymal transition in gastric cancer (Review). International Journal of Oncology, 27(6), 1677–1683.

Koch, A., Joosten, S. C., Feng, Z., de Ruijter, T. C., Draht, M. X., Melotte, V., Smits, K. M., Veeck, J., Herman, J. G., Van Neste, L., Van Criekinge, W., de Meyer, T., & van Engeland, M. (2018). Author Correction: Analysis of DNA methylation in cancer: location revisited. Nature Reviews. Clinical Oncology, 15(7), 467–467. https://doi.org/10.1038/s41571-018-0028-9

Kodera, Y., Nakanishi, H., Ito, S., Yamamura, Y., Kanemitsu, Y., Shimizu, Y., Hirai, T., Yasui, K., Kato, T., & Tatematsu, M. (2002). Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Annals of Surgery, 235(4), 499–506. https://doi.org/10.1097/00000658-200204000-00007

Li, Z., & Guo, Z. (2020). Comparison of CDH1 gene hypermethylation status in blood and serum among gastric cancer patients. Pathology Oncology Research: POR, 26(2), 1057–1062. https://doi.org/10.1007/s12253-019-00658-5

Ling, Z.-Q., Li, P., Ge, M.-H., Zhao, X., Hu, F.-J., Fang, X.-H., Dong, Z.-M., & Mao, W.-M. (2011). Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer. International Journal of Molecular Medicine, 27(5), 625–635. https://doi.org/10.3892/ijmm.2011.640

Lisiecki, R., Kruszwicka, M., Spychała, A., & Murawa, D. (2017). Prognostic significance, diagnosis and treatment in patients with gastric cancer and positive peritoneal washings. A review of the literature. Reports of Practical Oncology and Radiotherapy: Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 22(6), 434–440. https://doi.org/10.1016/j.rpor.2017.08.004

Liu, D., Lu, M., Li, J., Yang, Z., Feng, Q., Zhou, M., Zhang, Z., & Shen, L. (2016). The patterns and timing of recurrence after curative resection for gastric cancer in China. World Journal of Surgical Oncology, 14(1), 305. https://doi.org/10.1186/s12957-016-1042-y

Lu F., Du G., Zheng S., Peng L., & Chen J. (2014). Detection of CDH1 gene methylation of suspension cells in abdominal lavage fluid from colorectal cancer patients and its clinical significance. Zhonghua wei chang wai ke za zhi [Chinese journal of gastrointestinal surgery], 17(11), 1133–1136.

Ma, Y. R., Siegal, G. P., & Wei, S. (2017). Reacquisition of E-cadherin expression in metastatic deposits of signet-ring cell carcinoma of the upper gastrointestinal system: a potential anchor for metastatic deposition. Journal of Clinical Pathology, 70(6), 528–532. https://doi.org/10.1136/jclinpath-2016-203959

Nojima, D., Nakajima, K., Li, L. C., Franks, J., Ribeiro-Filho, L., Ishii, N., & Dahiya, R. (2001). CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Molecular Carcinogenesis, 32(1), 19–27. https://doi.org/10.1002/mc.1060

Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.

Paolillo, M., & Schinelli, S. (2019). Extracellular matrix alterations in metastatic processes. International Journal of Molecular Sciences, 20(19), 4947. https://doi.org/10.3390/ijms20194947

Pathogenesis and treatment of Gastric Carcinoma: “An up-date with brief review”. (2007). The Internet journal of oncology, 4(1). https://doi.org/10.5580/490

Peixoto, P., Etcheverry, A., Aubry, M., Missey, A., Lachat, C., Perrard, J., Hendrick, E., Delage-Mourroux, R., Mosser, J., Borg, C., Feugeas, J.-P., Herfs, M., Boyer-Guittaut, M., & Hervouet, E. (2019). EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death & Disease, 10(3), 205. https://doi.org/10.1038/s41419-019-1397-4

Prieto-García, E., Díaz-García, C. V., García-Ruiz, I., & Agulló-Ortuño, M. T. (2017). Epithelial-to-mesenchymal transition in tumor progression. Medical Oncology (Northwood, London, England), 34(7), 122. https://doi.org/10.1007/s12032-017-0980-8

Prudkin, L., Liu, D. D., Ozburn, N. C., Sun, M., Behrens, C., Tang, X., Brown, K. C., Bekele, B. N., Moran, C., & Wistuba, I. I. (2009). Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 22(5), 668–678. https://doi.org/10.1038/modpathol.2009.19

Rohde, C., Zhang, Y., Jurkowski, T. P., Stamerjohanns, H., Reinhardt*, R., & Jeltsch, A. (2008). Bisulfite sequencing Data Presentation and Compilation (BDPC) web server a useful tool for DNA methylation analysis. GBM Annual Spring meeting Mosbach 2008, 2008(Spring). https://doi.org/10.1240/sav_gbm_2008_m_002251

Sawada, T., Yashiro, M., Sentani, K., Oue, N., Yasui, W., Miyazaki, K., Kai, K., Fushida, S., Fujimura, T., Ohira, M., Kakeji, Y., Natsugoe, S., Shirabe, K., Nomura, S., Shimada, Y., Tomita, N., Hirakawa, K., & Maehara, Y. (2015). New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 18(1), 119–128. https://doi.org/10.1007/s10120-014-0338-2

Shenoy, S. (2019). CDH1 (E-cadherin) mutation and gastric cancer: Genetics, molecular mechanisms and guidelines for management. Cancer Management and Research, 11, 10477–10486. https://doi.org/10.2147/CMAR.S208818

Soleyman-Jahi, S., Nedjat, S., Abdirad, A., Hoorshad, N., Heidari, R., & Zendehdel, K. (2014). Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: a meta-analysis. PloS One, 10(4), e0122316. https://doi.org/10.1371/journal.pone.0122316

Suzuki, H., Itoh, F., Toyota, M., Kikuchi, T., Kakiuchi, H., Hinoda, Y., & Imai, K. (1999). Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. International Journal of Cancer. Journal International Du Cancer, 83(3), 309–313. https://doi.org/10.1002/(sici)1097-0215(19991029)83:3<309::aid-ijc4>3.0.co;2-z

Tamura, G., Yin, J., Wang, S., Fleisher, A. S., Zou, T., Abraham, J. M., Kong, D., Smolinski, K. N., Wilson, K. T., James, S. P., Silverberg, S. G., Nishizuka, S., Terashima, M., Motoyama, T., & Meltzer, S. J. (2000). E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. Journal of the National Cancer Institute, 92(7), 569–573. https://doi.org/10.1093/jnci/92.7.569

Thomassen, I., van Gestel, Y. R., van Ramshorst, B., Luyer, M. D., Bosscha, K., Nienhuijs, S. W., Lemmens, V. E., & de Hingh, I. H. (2014). Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors: Peritoneal Carcinomatosis of Gastric Origin. International Journal of Cancer. Journal International Du Cancer, 134(3), 622–628. https://doi.org/10.1002/ijc.28373

Venza, M., Visalli, M., Catalano, T., Biondo, C., Beninati, C., Teti, D., & Venza, I. (2016). DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma. Oncology Reports, 35(4), 2451–2460. https://doi.org/10.3892/or.2016.4618

Virgilio, E., Giarnieri, E., Giovagnoli, M. R., Montagnini, M., Proietti, A., D’Urso, R., Mercantini, P., Valabrega, S., Balducci, G., & Cavallini, M. (2018). Gastric cancer cells in peritoneal lavage fluid: A systematic review comparing cytological with molecular detection for diagnosis of peritoneal metastases and prediction of peritoneal recurrences. Anticancer Research, 38(3), 1255–1262. https://doi.org/10.21873/anticanres.12347

Vleminckx, K., Vakaet, L., Jr, Mareel, M., Fiers, W., & van Roy, F. (1991). Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 66(1), 107–119. https://doi.org/10.1016/0092-8674(91)90143-m

Yoo, C. H., Noh, S. H., Shin, D. W., Choi, S. H., & Min, J. S. (2000). Recurrence following curative resection for gastric carcinoma: Recurrence of gastric cancer afer resection. The British Journal of Surgery, 87(2), 236–242. https://doi.org/10.1046/j.1365-2168.2000.01360.x

Yu, Q.-M., Wang, X.-B., Luo, J., Wang, S., Fang, X.-H., Yu, J.-L., & Ling, Z.-Q. (2012). CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer: CDH1 Methylation Predicts Poor Prognosis. Journal of Surgical Oncology, 106(6), 765–771. https://doi.org/10.1002/jso.23116

Zeng, W., Zhu, J., Shan, L., Han, Z., Aerxiding, P., Quhai, A., Zeng, F., Wang, Z., & Li, H. (2015). The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review. Drug Design, Development and Therapy, 9, 2149–2157. https://doi.org/10.2147/DDDT.S75429

Zhu, B.-Y., Yuan, S.-Q., Nie, R.-C., Li, S.-M., Yang, L.-R., Duan, J.-L., Chen, Y.-B., & Zhang, X.-S. (2019). Prognostic factors and recurrence patterns in T4 gastric cancer patients after curative resection. Journal of Cancer, 10(5), 1181–1188. https://doi.org/10.7150/jca.28993

Descargas

Publicado

25/01/2022

Cómo citar

OLIVEIRA, A. C. F. M. de .; MODESTO, A. A. C. .; MOREIRA, F. C. .; ARAÚJO, T. M. T. .; SILVA, M. G. de O. P. da .; ASSUMPÇÃO, P. P. .; ISHAK, G.; BORGES, B. do N. .; KHAYAT, A. S. . Metilación de CDH1 en lavados peritoneales como factor pronóstico de cáncer gástrico. Research, Society and Development, [S. l.], v. 11, n. 2, p. e27911225758, 2022. DOI: 10.33448/rsd-v11i2.25758. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/25758. Acesso em: 8 jul. 2024.

Número

Vol. 11 Núm. 2

Sección

Ciencias de la salud

Licencia

Derechos de autor 2022 Ana Carolina Favacho Miranda de Oliveira; Antonio André Conde Modesto; Fabiano Cordeiro Moreira; Taíssa Maíra Thomaz Araújo; Marcelli Geise de Oliveira Prata da Silva; Paulo Pimentel Assumpção; Geraldo Ishak; Bárbara do Nascimento Borges; André Salim Khayat

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Los autores que publican en esta revista concuerdan con los siguientes términos:

1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.

2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.

3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.